Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug candidate enters early human testing

NCT ID NCT06606106

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and how the body handles the drug. Researchers will also measure weight changes and blood sugar levels. The study involves about 300 people and lasts up to 49 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LY3537031 (a drug given as an injection under the skin)
What this could lead to
If this early study shows the drug is safe and leads to weight loss, it could point toward a new treatment for obesity.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not weight loss. The drug may not work or could have side effects. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 302 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a BMI within the range of: * Parts A and D: 27.0 to 45.0 kilogram per square meter (kg/m²) * Parts B and C: 22.0 to 26.9 kg/m² * Parts B and C: Weigh 60 kg (80 pounds (lbs)) or more at screening * Have no significant (not more than 5%) self-reported weight gain or loss in the past 3 months prior to screening * Have a thyroid stimulating hormone (TSH) value within normal local laboratory ranges. Exclusion Criteria: * Have undergone any form of bariatric surgery * Participants who are lactating * Have taken medications that promote weight loss within 90 days before screening * Have a serum calcitonin level (at screening) of greater than or equal to 35 nanograms per liter (ng/L) (35 picograms per milliliter (pg/mL), 10.2 picomoles per liter (pmol/L))

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy Obesity Overweight

Contacts and locations

Locations

  • Clinical Pharmacology of Miami

    Miami, Florida, 33172, United States

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California, 90720, United States

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida, 32117, United States

  • Fortrea Clinical Research Unit

    Dallas, Texas, 75247, United States

  • QPS

    Springfield, Missouri, 65802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.